Alexion announced the publication of data from the phase 3 open-label extension of the REGAIN trial (ECU-MG-302) that assessed the long-term safety and efficacy of eculizumab (Soliris) for the treatment of adults with anti-acetylcholine receptor (AChR) antibody-positive refractory generalized myasthenia gravis (gMG).
The serum neurofilament light chain levels were significantly higher in patients with MS with evidence of disease activity compared with patients with no evidence of disease and healthy controls.
EMD Serono announced that the Food and Drug Administration (FDA) has approved Mavenclad (cladribine) tablets for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (SPMS).
The FDA has approved siponimod for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Investigators of this retrospective study sought to compare the risk of incident AMI in patients with MS vs a matched cohort without MS, controlling for traditional cardiovascular risk factors.
The majority of treatment-related cases of immune thrombocytopenia can be remedied with the use of corticosteroids, platelets, or intravenous immunoglobulin.
